THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

William Sandborn  ¹     Daphne Chan  ²     Jewel Johanns  ²     Grace Lang  ²     Omoniyi J. Adedokun  ²     Anita Afzali  ³     Jane Andrews  ⁴     Geert R. D'Haens  ⁵     Silvio Danese  ⁶     Tadakazu Hisamatsu  ⁷     Remo Panaccione  ⁸     Julian Panés  ⁹     Walter Reinisch  ¹⁰     David T. Rubin  ¹¹     Bruce E. Sands  ¹²     Brian G. Feagan  ^13    
1 University of California San Diego, La Jolla, United States
² Janssen Research & Development, LLC, Spring House, United States
³ The Ohio State University Wexner Medical Center, Columbus, United States
⁴ Royal Adelaide Hospital, Adelaide, Australia
⁵ Amsterdam UMC, Amsterdam, Netherlands
⁶ Humanitas Research Hospital, Milan, Italy
⁷ Kyorin University, Tokyo, Japan
⁸ University of Calgary, Calgary, Canada
⁹ Hospital Clinic Barcelona, Barcelona, Spain
¹⁰ Medical University of Vienna, Vienna, Austria
¹¹ University of Chicago Medicine, Chicago, United States
¹² Icahn School of Medicine at Mount Sinai, New York, United States
¹³ Robarts Clinical Trials Inc., London, Canada

Topic
IBD, Immunology

Session
IBD: Clinical trials I

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)